Innovations in Oncology: Gastrointestinal Cancers

How could emerging data on novel immuno-oncology (IO) strategies change your approach to therapy?

This educational series examines the current role of immunotherapy in gastric cancers and explores the future direction of IO therapy in treatment. Our globally renowned experts provide an update on advances to care that you can apply to your practice today. They also review National Comprehensive Cancer Network guidelines pertaining to patients with MSI-H/dMMR or HER2+ colorectal cancer; gastric, esophageal, and gastroesophageal junction cancers; and advanced hepatocellular carcinoma.

Provided by:

In Partnership with:

LikeLikedUnlike

Episodes 1-3 of 3

- Richard S. Finn, MD
  Peer
- Peter R. Galle, MD
  Peer
2
CME/CE
Optimizing Care for Patients with Advanced Hepatocellular Carcinoma: Current Standards and Future Directions with Immunotherapy
Optimizing Care for Patients with Advanced Hepatocellular Carcinoma: Current Standards and Future Directions with Immunotherapy
0.50 credits
- Eric Van Cutsem, MD, PhD
  Peer
- Elizabeth Smyth, MD
  Peer
- Sunnie Kim, MD
  Peer
6
CME/CE
Immune-Based Advances in Gastric, Esophageal, and Gastroesophageal Junction Cancers
Immune-Based Advances in Gastric, Esophageal, and Gastroesophageal Junction Cancers
0.50 credits
- Aparna R. Parikh, MD
  Peer
- Dustin Deming, MD
  Peer
- Scott Kopetz, MD, PhD
  Peer
1
CME/CE
Advances in the Care of Patients with MSI-H/dMMR or HER2+ Colorectal Cancers
Advances in the Care of Patients with MSI-H/dMMR or HER2+ Colorectal Cancers
0.50 credits